Health TrialsbyHealthPanel

Muscle Relaxant Effect and Safety of Mivacurium Chloride and Succinylcholine for Bronchoscopy

ConditionsAnesthesiaBronchoscopyMuscle Relaxants
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorPeng Liang

About this trial

The goal of this clinical trial is to evaluate whether mivacurium chloride and succinylcholine can provide effective and safe muscle relaxation in adult patients aged 18-60 years undergoing bronchoscopy who require muscle relaxants during anesthesia. The main questions it aims to answer are:

* Is the recovery of spontaneous breathing within 15 minutes after drug discontinuation with mivacurium chloride non-inferior to succinylcholine? * How do mivacurium chloride and succinylcholine compare in terms of intraoperative hemodynamics and post-operative recovery and comfort? Researchers will compare the mivacurium chloride group and the succinylcholine group to observe if mivacurium chloride can provide similar or better recovery effects compared to succinylcholine.

Participants will:

* Receive either mivacurium chloride (0.14 mg/kg induction bolus + 0.5 mg/kg/h maintenance infusion) or succinylcholine (1 mg/kg induction bolus + 5 mg/kg/h maintenance infusion) as a muscle relaxant during bronchoscopy. * Have their vital signs, including blood pressure, oxygen saturation, and heart rate, monitored at multiple time points during the procedure. * Be assessed post-procedure for spontaneous breathing recovery, consciousness recovery, and time to laryngeal mask airway (LMA) removal, as well as overall comfort and satisfaction.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Patients scheduled for painless bronchoscopy who require muscle relaxants during anesthesia.

Aged between 18 and 60 years.

Classified as Grade I-III according to the American Society of Anesthesiologists (ASA) Physical Status Classification.

Patients voluntarily participate and sign an informed consent form.

Disqualifiers

Patients with known allergies to any of the drugs involved in the study.

Patients with severe organic diseases of the brain, heart, lungs, liver, kidneys, or other major organs.

Patients with intracranial hypertension, asthma, cataracts, glaucoma, or other eye diseases.

Patients with myasthenia gravis, myasthenic syndrome, severe reduction or deficiency of cholinesterase, upper motor neuron injury, or upper motor neuron diseases that may cause abnormal responses to muscle relaxants.

Trial design

Design model

Parallel

Treatments tested in this trial

  • mivacurium chloride

    Drug

    mivacurium chloride 0.14 mg/kg induction bolus + 0.5 mg/kg/h maintenance infusion

  • succinylcholine

    Drug

    succinylcholine (1 mg/kg induction bolus + 5 mg/kg/h maintenance infusion)

Treatment groups

240 Participants
are divided into 2 treatment groups
Group A: mivacurium chlorideExperimental treatment 1 intervention
Group B: succinylcholineActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Rate of spontaneous breathing recovery

The rate of spontaneous breathing recovery after discontinuation of mivacurium chloride and succinylcholine during bronchoscopy.

Time frame
Within 15 minutes after the completion of bronchoscopy.

Secondary outcomes

1

Recovery time of spontaneous breathing

Comparison of recovery times (minutes) for spontaneous breathing between mivacurium chloride and succinylcholine groups. Spontaneous breathing recovery is defined as achieving a tidal volume of 5 ml/kg and a respiratory rate of 12 breaths per minute.

Time frame
From the end of bronchoscopy until spontaneous breathing, assessed up to 15 minutes post-procedure.
2

Recovery time of consciousness

Comparison of recovery times (minutes) for consciousness recovery. Consciousness recovery is defined as the ability to open eyes upon verbal command or when called by name.

Time frame
From the end of bronchoscopy until each specific recovery milestone is achieved, assessed up to 15 minutes post-procedure.
3

Laryngeal mask airway (LMA) removal time

Comparison of time to remove laryngeal mask airway (LMA) between mivacurium chloride and succinylcholine groups.

Time frame
From the end of bronchoscopy until each specific recovery milestone is achieved, assessed up to 15 minutes post-procedure.
4

Mean pulse pressure at different stages

Blood pressure measurements should be taken at 1-minute intervals during the induction phase (pre-LMA insertion), until the LMA is inserted. For the pre-induction phase, post-LMA insertion, surgery start, surgery end, and post-LMA removal, blood pressure should be measured every 3 minutes, with recordings taken for a total of 3 minutes at each stage. The average blood pressure (mmHg) for each stage was calculated using the values recorded during that stage for both the mivacurium chloride and succinylcholine groups.

Time frame
3 minutes before induction, 1-minute intervals during induction until the LMA is inserted, 3 minutes after LMA insertion, 3 minutes after surgery start, 3 minutes after surgery end, and 3 minutes after LMA removal.

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Peng Liang

Lead sponsor

West China Hospital

Sponsor institution

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: